• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tenapanor for the Treatment of Hyperphosphatemia in Japanese Hemodialysis Patients: A Randomized Phase 3 Monotherapy Study With an Up-titration Regimen.

作者信息

Fukagawa Masafumi, Urano Natsuki, Ikejiri Kazuaki, Kinoshita Jun, Nakanishi Kaoru, Akizawa Tadao

机构信息

Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.

R&D Division, Kyowa Kirin Co, Ltd, Tokyo, Japan.

出版信息

Am J Kidney Dis. 2023 Nov;82(5):635-637. doi: 10.1053/j.ajkd.2023.03.019. Epub 2023 Jun 15.

DOI:10.1053/j.ajkd.2023.03.019
PMID:37330134
Abstract
摘要

相似文献

1
Tenapanor for the Treatment of Hyperphosphatemia in Japanese Hemodialysis Patients: A Randomized Phase 3 Monotherapy Study With an Up-titration Regimen.替那帕诺治疗日本血液透析患者高磷血症：一项采用滴定递增方案的随机3期单药治疗研究。
Am J Kidney Dis. 2023 Nov;82(5):635-637. doi: 10.1053/j.ajkd.2023.03.019. Epub 2023 Jun 15.
2
Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial.日本接受血液透析的高磷血症患者中替那帕诺的剂量反应——一项2期随机试验
Kidney Int Rep. 2021 Nov 24;7(2):177-188. doi: 10.1016/j.ekir.2021.11.008. eCollection 2022 Feb.
3
Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.在接受维持性血液透析的高磷血症患者中，他纳诺尔的疗效和安全性：一项随机 3 期试验。
J Am Soc Nephrol. 2019 Apr;30(4):641-652. doi: 10.1681/ASN.2018080832. Epub 2019 Mar 7.
4
Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: A systematic review and meta-analysis of randomized placebo-controlled trials.在血液透析高磷血症患者中使用替纳诺治疗的疗效和安全性：一项随机安慰剂对照试验的系统评价和荟萃分析。
Ther Apher Dial. 2023 Oct;27(5):839-847. doi: 10.1111/1744-9987.14028. Epub 2023 Jun 22.
5
Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.替那帕诺对接受血液透析患者血清磷酸盐的影响。
J Am Soc Nephrol. 2017 Jun;28(6):1933-1942. doi: 10.1681/ASN.2016080855. Epub 2017 Feb 3.
6
The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.在高磷血症接受血液透析的患者中，替纳普诺对血清成纤维细胞生长因子 23 的影响。
Nephrol Dial Transplant. 2019 Feb 1;34(2):339-346. doi: 10.1093/ndt/gfy061.
7
Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease.特立帕肽：终末期肾病高磷血症的新治疗选择。
J Pharm Pharm Sci. 2022;25:77-83. doi: 10.18433/jpps32284.
8
A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).一项关于特立帕肽联合磷酸盐结合剂作为维持性透析患者高磷血症双联治疗的随机试验（AMPLIFY）
J Am Soc Nephrol. 2021 Jun 1;32(6):1465-1473. doi: 10.1681/ASN.2020101398. Epub 2021 Mar 25.
9
Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients.替那帕诺对血液透析患者磷结合剂药丸负担的影响。
Kidney Int Rep. 2021 Jul 8;6(9):2371-2380. doi: 10.1016/j.ekir.2021.06.030. eCollection 2021 Sep.
10
Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).Tenapanor 长期控制维持性透析患者血清磷酸盐水平的安全性和疗效：一项 52 周随机 3 期试验（PHREEDOM）。
Kidney360. 2021 Aug 27;2(10):1600-1610. doi: 10.34067/KID.0002002021. eCollection 2021 Oct 28.

引用本文的文献

1
Efficacy of tenapanor in managing hyperphosphatemia and constipation in hemodialysis patients: A randomized controlled trial.替那帕诺治疗血液透析患者高磷血症和便秘的疗效：一项随机对照试验。
PLoS One. 2025 Jun 17;20(6):e0319319. doi: 10.1371/journal.pone.0319319. eCollection 2025.
2
Tenapanor: A novel therapeutic agent for dialysis patients with hyperphosphatemia.替那帕诺：一种用于治疗透析高磷血症患者的新型治疗药物。
Ther Apher Dial. 2025 Apr;29(2):157-169. doi: 10.1111/1744-9987.14241. Epub 2025 Jan 19.
3
Efficacy and safety of tenapanor in end-stage renal disease patients with hyperphosphatemia: a systematic review and meta-analysis.
终末期肾病高磷血症患者使用替纳普仑的疗效和安全性：系统评价和荟萃分析。
Ren Fail. 2024 Dec;46(2):2410389. doi: 10.1080/0886022X.2024.2410389. Epub 2024 Oct 1.
4
Oh, My Gut! New insights on the role of the gastrointestinal tract and the gut microbiome in chronic kidney disease-mineral and bone disorder.哦，我的肠道！关于胃肠道和肠道微生物群在慢性肾脏病 - 矿物质和骨异常中作用的新见解
Curr Opin Nephrol Hypertens. 2024 Mar 1;33(2):226-230. doi: 10.1097/MNH.0000000000000961. Epub 2023 Dec 13.
5
Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia.在难治性高磷血症患者中添加替那帕诺至磷结合剂的随机研究。
Kidney Int Rep. 2023 Aug 13;8(11):2243-2253. doi: 10.1016/j.ekir.2023.08.003. eCollection 2023 Nov.
6
Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia.长期应用替班那诺治疗血液透析高磷血症患者的安全性和减少药物负担：一项 3 期开放性研究。
Sci Rep. 2023 Nov 4;13(1):19100. doi: 10.1038/s41598-023-45080-9.
7
Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial.用于高磷血症腹膜透析患者的替纳诺尔：一项 3 期试验。
Clin Exp Nephrol. 2024 Feb;28(2):153-164. doi: 10.1007/s10157-023-02406-1. Epub 2023 Nov 1.